Half-year report · Q2
4564.TEDINET S100UOSE
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥356m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥695m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥708m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥709m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥711m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥548m | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥514m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥935m | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥528m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥881m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥880m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥677m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.42 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥149,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥183m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥109m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥537,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥387,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥403m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥357m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥356m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥149,000 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥512m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 411
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -236192000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 570617000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1117635000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 527656000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 881443000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1098274000 | JPY |
| Taxes and dues sga | Prior1YTDDuration | 72125000 | JPY |
| Taxes and dues sga | CurrentYTDDuration | 76322000 | JPY |
| Commission fee sga | Prior1YTDDuration | 39969000 | JPY |
| Commission fee sga | CurrentYTDDuration | 46320000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 387000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 356064000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 356452000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 356452000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 149000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 149000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -149000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 537000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 356064000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 356602000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -149000 | JPY |
| Net sales | Prior1YTDDuration | 356452000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -403450000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -108528000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -511979000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -182779000 | JPY |
| Operating income | Prior1YTDDuration | -694759000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 2970000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 222113000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 225083000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 225083000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 135000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 135000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -135000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 3105000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 222113000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 225219000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -135000 | JPY |
| Net sales | CurrentYTDDuration | 225083000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -259122000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -93553000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -352676000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -178441000 | JPY |
| Operating income | CurrentYTDDuration | -531117000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |